Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of LPCN opened at $3.56 on Tuesday. Lipocine has a 1 year low of $3.20 and a 1 year high of $11.79. The stock has a 50 day simple moving average of $4.51 and a two-hundred day simple moving average of $4.62. The firm has a market cap of $19.04 million, a P/E ratio of -4.68 and a beta of 1.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC lifted its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.